Background: Metastatic malignancy occurs rarely in the colon or rectum. We presented 14 patients with colorectal metastasis (CRM). Methods: A retrospective review was conducted on a computerized colorectal tumor database at the Taipei Veterans General Hospital from January 2000 to June 2013. Results: The incidence of CRM was 0.19% (14 in 7,524 patients). There were 6 males and 8 females with a mean age of 66.9 ± 13.6 years. Origins of the CRM included lung cancers (n = 3), prostate cancers (n = 2), and others (n = 1, respectively). Clinical presentations were not specific and colonoscopic pictures were indistinguishable from primary colorectal cancers; 5 of the 9 biopsies identified metastasis. Eight patients had extracolonic metastasis and 6 patients had CRM only. Significantly better survival was observed in the CRM-only group (p = 0.037). The mean interval from the treatment of primary tumor to the diagnosis of CRM was 30.2 ± 49.0 months. The mean survival time after CRM was 24.9 ± 30.8 months. Conclusion: Clinical features and colonoscopic findings of CRM were indistinguishable from primary colorectal cancer. Histopathological review of the biopsy could be helpful in identifying the primary lesion. Surgical resection with curative intent provided longer survival in CRM-only patients.

1.
Berge T, Lundberg S: Cancer in malmö 1958-1969. An autopsy study. Acta Pathol Microbiol Scand Suppl 1977;260:1-235.
2.
Caramella E, Bruneton JN, Roux P, Aubanel D, Lecomte P: Metastases of the digestive tract. Report of 77 cases and review of the literature. Eur J Radiol 1983;3:331-338.
3.
Dhar S, Kulaylat MN, Gordon K, Lall P, Doerr RJ: Solitary papillary breast carcinoma metastasis to the large bowel presenting as primary colon carcinoma: case report and review of the literature. Am Surg 2003;69:799-803.
4.
Hirasaki S, Suzuki S, Umemura S, Kamei H, Okuda M, Kudo K: Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test. World J Gastroenterol 2008;14:5481-5483.
5.
Yang CJ, Hwang JJ, Kang WY, Chong IW, Wang TH, Sheu CC, Tsai JR, Huang MS: Gastro-intestinal metastasis of primary lung carcinoma: clinical presentations and outcome. Lung Cancer 2006;54:319-323.
6.
Rees BI, Okwonga W, Jenkins IL: Intestinal metastases from carcinoma of the breast. Clinical Oncol 1976;2:113-119.
7.
Mourra N, Jouret-Mourin A, Lazure T, Audard V, Albiges L, Malbois M, Bouzourene H, Duvillard P: Metastatic tumors to the colon and rectum: a multi-institutional study. Arch Pathol Lab Med 2012;136:1397-1401.
8.
Rabau MY, Alon RJ, Werbin N, Yossipov Y: Colonic metastases from lobular carcinoma of the breast. Report of a case. Dis Colon and Rectum 1988;31:401-402.
9.
Law WL, Chu KW: Scirrhous colonic metastasis from ductal carcinoma of the breast: report of a case. Dis Colon Rectum 2003;46:1424-1427.
10.
Melnick GS, Rosenholtz MJ: Metastatic breast carcinoma simulating ulcerative colitis. Report of a case. Am J Roentgenol Radium Ther Nucl Med 1961;86:702-706.
11.
Koos L, Field RE: Metastatic carcinoma of breast simulating Crohn's disease. Int Surg 1980;65:359-362.
12.
Graham WP 3rd: Gastro-intestinal metastases from carcinoma of the breast. Ann Surg 1964;159:477-480.
13.
Yang CW, Liang WY, Lin JK, Chiou TJ, Lee CH, Jiang JK: Colonic metastasis from a papillary thyroid carcinoma arising in struma ovarii. Int J Colorectal Dis 2010;25:913-914.
14.
McLemore EC, Pockaj BA, Reynolds C, Gray RJ, Hernandez JL, Grant CS, Donohue JH: Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol 2005;12:886-894.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.